Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Allergan plc (NYSE:AGN)

243.94
Delayed Data
As of Sep 23
 +0.51 / +0.21%
Today’s Change
195.50
Today|||52-Week Range
322.68
-21.94%
Year-to-Date
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
Sep 24 / MotleyFool.com - Paid Partner Content
Why Tobira Therapeutics Inc Was an Overnight Octuple
Sep 20 / MotleyFool.com - Paid Partner Content
Dow 30 Stock Roundup: Microsoft Rewards Shareholders; GE Wins $1.9B Nuclear Power Con...
Sep 23 / Zacks.com - Paid Partner Content
Sarepta jumps after drugs regulator boost
Sep 20 / FT.com - Paid Partner Content
ETFs in Focus on the Nasdaq Rally
Sep 23 / Zacks.com - Paid Partner Content
Stocks Post Modest Gains as Fed Meets, Crude Higher
Sep 20 / TheStreet.com - Paid Partner Content
Allergan/Adamas Launch New Dosage Strengths of Namzaric
Sep 23 / Zacks.com - Paid Partner Content
Allergan's Chart Is Not Persuasive
Sep 20 / TheStreet.com - Paid Partner Content
US politicians lament inaction over price-gouging drug companies
Sep 23 / FT.com - Paid Partner Content
More Squawk from Jim Cramer: Allergan (AGN) Buying Tobira (TBRA) Looks Like 'Such an ...
Sep 20 / TheStreet.com - Paid Partner Content
Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
Sep 23 / Zacks.com - Paid Partner Content
Allergan (AGN) Stock Down After Tobira Therapeutics Deal
Sep 20 / TheStreet.com - Paid Partner Content
Allergan's Vitae buy could spark more interest in Kadmon
Sep 23 / TheStreet.com - Paid Partner Content
Stocks Rise as Federal Reserve Meeting Begins
Sep 20 / TheStreet.com - Paid Partner Content
Wallace Weitz's Largest 2nd-Quarter Trades
Sep 22 / GuruFocus News - Paid Partner Content
Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biog...
Sep 20 / TheStreet.com - Paid Partner Content
The Good, the Bad and the Ugly in Today's Market
Sep 22 / TheStreet.com - Paid Partner Content
Jeff Auxier Buys Biogen, LyondellBasell and Union Pacific
Sep 19 / GuruFocus News - Paid Partner Content
5 Biotech Stocks to Watch as Interest in NASH Increases
Sep 22 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
Sep 16 / Zacks.com - Paid Partner Content
Is Galectin The Next Takeover Target for the Biotech World?
Sep 22 / Zacks.com - Paid Partner Content
Stock Market News for September 15, 2016
Sep 15 / Zacks.com - Paid Partner Content
Jim Cramer's Top Takeaways: Flex, Walt Disney, Allergan
Sep 22 / TheStreet.com - Paid Partner Content
Company News for September 15, 2016
Sep 15 / Zacks.com - Paid Partner Content
Allergan's Boldness may not be Limited to Tobira Deal
Sep 21 / TheStreet.com - Paid Partner Content
Allergan to Buy Vitae Pharma to Boost Dermatology Suite
Sep 15 / Zacks.com - Paid Partner Content
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sep 21 / Zacks.com - Paid Partner Content
What Happened in the Stock Market Today
Sep 14 / MotleyFool.com - Paid Partner Content
Stock Market News for September 21, 2016
Sep 21 / Zacks.com - Paid Partner Content
Coach slips on 'unhealthy manner' warning
Sep 14 / FT.com - Paid Partner Content
Stock Futures Rise as Bank of Japan Tackles Deflation
Sep 21 / TheStreet.com - Paid Partner Content
Bayer Monsanto deal requires jumbo financing
Sep 14 / FT.com - Paid Partner Content
Allergan Buys NASH Therapy Maker Tobira at Huge Premium
Sep 21 / Zacks.com - Paid Partner Content
Here's Why Shares of Vitae Pharmaceuticals Inc Are Skyrocketing Today
Sep 14 / MotleyFool.com - Paid Partner Content
Why Did Tobira Therapeutics (TBRA) Stock Skyrocket 720% Today?
Sep 20 / Zacks.com - Paid Partner Content
Bayer Finally Buys Monsanto, Inflation Vanishes
Sep 14 / Zacks.com - Paid Partner Content
Why DTS, SolarCity, and Tobira Therapeutics Jumped Today
Sep 20 / MotleyFool.com - Paid Partner Content
Why Allergan Should Start Paying a Dividend
Sep 13 / MotleyFool.com - Paid Partner Content
How Will Allergan (AGN) Stock React to Akarna Therapeutics Deal?
Sep 20 / TheStreet.com - Paid Partner Content
'Middlemen' under the spotlight in EpiPen furore
Sep 09 / FT.com - Paid Partner Content
My Takeaways and Observations
Sep 20 / TheStreet.com - Paid Partner Content
CEO of Botox maker vows to limit price hikes
Sep 07 / CNNMoney.com
Wall Street Creeps Higher Ahead of Fed Decision
Sep 20 / TheStreet.com - Paid Partner Content